Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224234 · ClinicalTrials.gov registry record · NA
A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 121
- Enrollment target
NCT03224234 is a NA study that has completed, run by Emory University. The registered enrollment target is 121 participants.
The verdict
NCT03224234, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 121 participants
- Enrollment target
Study Summary
Poor adherence to insulin regimens is reported in up to two-third of patients with diabetes; thus it is important to identify patients at risk and to develop strategies and tools to increase adherence to prescribed insulin regimens. This study will evaluate the efficacy of Insulclock® - small electronic device to help track date, time and dosage of the last injection, type of insulin used and temperature, with an alarm system to prevent insulin omissions and mistiming.
Interventions
- DEVICE Insulclock with feedback
- DEVICE Insulclock without feedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2019-09-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03224234
The ClinicalTrials.gov registry entry for NCT03224234 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulclock with feedback is the first listed.
NCT03224234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03224234 about?
NCT03224234 is a clinical study titled "A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes". Poor adherence to insulin regimens is reported in up to two-third of patients with diabetes; thus it is important to identify patients at risk and to develop strategies and tools to increase adherence to prescribed insulin regimens. This study will evaluate the efficacy of Insulclock® - small electr...
What is the current status of trial NCT03224234?
This trial is currently completed. It is a NA study. The enrollment target is 121 participants. The study started on 2017-11-29. Estimated completion is 2019-09-18.
What interventions are being tested in trial NCT03224234?
The interventions under investigation include: Insulclock with feedback (DEVICE), Insulclock without feedback (DEVICE).
Who is sponsoring clinical trial NCT03224234?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.